{"id":"W2792921896","doi":"10.1111/jdv.14878","title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":193,"is_retracted":false,"has_abstract":true,"ca_institutions":"XLV Diagnostics (Canada); Probity Medical Research; Innovaderm (Canada)","funders":"Novartis Pharma; Novartis","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Psoriasis; Psoriatic arthritis; Adverse effect; Clinical trial; Internal medicine; Surgery; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002214504,0.0003437538,0.0007804515,0.0001601098,0.0002251004,0.0003446059,0.000151726,0.0003024401,0.002115465],"category_scores_gemma":[0.0008254671,0.0001508738,0.0005017388,0.0001750215,0.0002060892,0.0002526158,0.0001958543,0.000686246,0.0004071634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001442729,"about_ca_system_score_gemma":0.0002666507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002043297,"about_ca_topic_score_gemma":0.0007312786,"domain_scores_codex":[0.9995822,0.00019836,0.00003615147,0.00005048774,0.00007858434,0.00005432856],"domain_scores_gemma":[0.9992089,0.0001743375,0.0002990241,0.0000738129,0.00006302736,0.0001810139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2251566,0.01745831,0.1747916,0.001583154,0.002291534,0.0004998246,0.0005234072,0.002381396,0.1216693,0.0002816371,0.005522541,0.4478407],"study_design_scores_gemma":[0.03684187,0.3040703,0.6359,0.0001051812,0.0008071171,0.001929758,0.00007460176,0.00146892,0.0121336,0.0001153427,0.006507545,0.0000457804],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966602,0.00188829,0.0002482712,0.00006915668,0.00001285929,0.0001156827,0.0001996034,0.00002950319,0.0007764472],"genre_scores_gemma":[0.9982961,0.0003953288,0.0002927578,0.00008786939,0.00003270926,0.00006152552,0.0004236325,0.000004598445,0.0004054327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002214504,"threshold_uncertainty_score":0.0117116,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01132367033045054,"score_gpt":0.2304250217205764,"score_spread":0.2191013513901259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}